Ortin Global Peer Comparison

Ortin Global Ltd. exhibits significantly weaker financial metrics compared to its peers in the Pharmaceuticals & Drugs sector, characterized by zero revenue and earnings growth, negative PE ratio, and a lack of profitability. Its peers demonstrate robust growth and profitability, suggesting that Ortin is facing severe challenges in its operational and financial performance.

• • Ortin Global Ltd. shows no revenue or earnings growth, while peers like Mankind Pharma and Dr. Reddy's have strong growth metrics.
• • Ortin has a negative PE ratio and zero profitability metrics, contrasting sharply with profitable peers such as Sun Pharma and Cipla.
• • The company is financially distressed with no positive returns on equity, assets, or capital employed.

• • Mankind Pharma Ltd.: Highest revenue growth YoY (18.12%) and strong profitability metrics.
• • Dr. Reddy's Laboratories Ltd.: Strong profitability with a high ROE (21.76%) and low valuation ratios.
• • Cipla Ltd.: Solid growth (13.28% YoY) and attractive valuation (PEG of 0.35).